A Photothermally Triggered Cascade Nanodelivery Platform for On‐Demand Nitric Oxide Release in Targeted Hepatocellular Carcinoma Therapy
Researchers have engineered a gold nanocage‑based nanoplatform (GIL9R) that co‑encapsulates indocyanine green and L‑arginine and is surface‑functionalized with the HCC‑targeting peptide 9R‑P201. Upon near‑infrared irradiation, the platform produces localized heat, reactive oxygen species, and catalyzes nitric‑oxide release, delivering combined photothermal, photodynamic, and gas therapy. In vitro, GIL9R selectively kills HepG2 hepatocellular carcinoma cells while sparing normal hepatocytes, and in H22 tumor‑bearing mice it accumulates in tumors and markedly suppresses growth. The system demonstrated strong biosafety after intravenous administration, indicating translational potential.
Scientists Create Wearable Ultrasound to Continuously Monitor Babies in Womb
Scientists at Stanford and Oxford have unveiled UPatch, a wearable ultrasound patch that can continuously image a fetus for hours, capturing real‑time blood‑flow and heart‑rate data. In a proof‑of‑concept study involving 62 pregnant participants, the device’s measurements closely matched those...
Will Lab-Grown Sperm Let Infertile Men Have Children of Their Own?
A US start‑up, Paterna Biosciences, says it can turn testicular stem cells into sperm in the lab, potentially offering a solution for men whose infertility cannot be treated with existing methods. The company claims the technique could enable almost all...
Cheaper, Alternative Health Plans Are Having a Moment, but Critics Urge Caution
Rising ACA marketplace premiums have driven many consumers toward lower‑cost alternatives such as short‑term, fixed‑indemnity and health‑sharing plans that do not meet federal coverage standards. These plans offer minimal premiums—often under $350 a month—but provide limited benefits, caps on payments,...
Healthcare Consumerism Alone Didn’t Bend the Cost Curve. Here’s What It’s Missing.
Employers have relied on healthcare consumerism—high‑deductible plans, HSAs, and price‑transparency tools—to curb costs, but the approach has failed to bend the cost curve. Studies show HDHPs reduce overall utilization while also lowering evidence‑based care and raising preventable events, and HSAs...
STAT+: An AI Biotech CEO Sets the Record Straight on AI Drug Development Hype
BigHat Biosciences CEO Peyton Greenside says her firm can generate antibody designs in as little as 20 minutes using machine‑learning, far faster than the six‑hour demos often touted in the industry. However, she emphasizes that rapid design is only the...
Oticon Medical Launches Ponto Instant Portfolio to Expand Non-Surgical Bone Conduction Hearing Options
Oticon Medical unveiled the Ponto Instant portfolio, a non‑surgical bone‑conduction hearing solution that adds two new wearables: the Instant HearBand and the Instant SoundConnector. The HearBand offers a lightweight, behind‑the‑head design with adjustable sizing, while the SoundConnector lets users attach...
AMA: Healthcare 2026: What Is Driving 3D Printing in Dentistry Toward a $10BN Market Value?
Dentistry’s 3D printing market, valued at roughly $5.2 billion in 2024, is projected to approach $10 billion by 2033. Printer penetration in U.S. practices has risen to about 15%, up from virtually none a decade ago, while entry‑level system costs have collapsed...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion on Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment for metastatic colorectal cancer (mCRC) harboring BRAFV600E mutations. The Phase III BREAKWATER trial demonstrated a 51% reduction in...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion for Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment of BRAFV600E‑mutant metastatic colorectal cancer. The Phase III BREAKWATER trial showed a 51 % reduction in death risk, extending median...
The European CDMO Model, Powering Biologics Innovation
European contract development and manufacturing organisations (CDMOs) are becoming pivotal as biologics grow in complexity, and 3PBIOVIAN exemplifies this shift with a pan‑European, end‑to‑end model. The company operates GMP‑certified facilities in Pamplona, Spain, and Turku, Finland, offering microbial, mammalian, viral...
AstraZeneca Receives the CHMP Positive Opinion for Camizestrant to Treat Advanced Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on AstraZeneca’s oral selective estrogen receptor degrader camizestrant, to be used with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer harboring ESR1 mutations....
Imaging Societies Clash over Bill to Require that Docs Consult Appropriate-Use Criteria
The American College of Radiology (ACR) is championing the Radiology Outpatient Ordering Transmission (ROOT) Act, legislation that would revive the CMS appropriate‑use criteria (AUC) program for advanced imaging. ACR CEO Dana H. Smetherman testified that the bill could save the...
Lantheus Weighs Potential Sale with $7B Valuation
Lantheus Holdings, a leading radiopharmaceutical developer, is reportedly entertaining a sale that could fetch a valuation close to $7 billion. Bloomberg cited sources saying Curium Pharma, a nuclear‑medicine specialist owned by CapVest Partners, is the primary suitor. Both companies have declined...
ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones
ONWARD Medical reported Q1 2026 results, delivering 70 ARC‑EX systems and expanding availability to over 100 clinics across the US and Europe. The company launched the Empower BP pivotal study, enrolling its first participant and activating 12 sites to evaluate the ARC‑IM...
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug‑design engine, while CellCentric secured $220 million to push its oral myeloma candidate, inobrodib, into Phase 3 trials. NVision raised $55 million Series B to merge quantum computing with its POLARIS MRI platform, aiming...
Novartis Breaks Ground On Denton, Texas Radioligand Therapy Site
Novartis broke ground on a 46,000‑sq‑ft radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking its first Texas‑based plant and the fifth RLT site in the United States. The project is part of a broader $23 billion five‑year investment to expand...
REGENXBIO, Novartis, Dyne Near FDA Submissions in Muscular Dystrophies
A wave of near‑term regulatory activity is reshaping the muscular dystrophy landscape. REGENXBIO reported mixed Phase 3 data for its gene therapy RGX‑202, achieving 93% microdystrophin expression but raising safety flags, while targeting a 2027 launch. Novartis’ $12 billion acquisition of Avidity...
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Australian biotech Noxopharm announced new data on its Sofra platform, a TLR8‑activating oligonucleotide technology that could enhance cancer immunotherapy. Preclinical studies demonstrated up to a 200‑fold boost in TLR8 activity in human skin biopsies and nearly three‑fold activation in animal...
NeuroScientific Hails 80% Clinical Response in Crohn’s Stem Cell Program
NeuroScientific Biopharmaceuticals reported that four of five patients with fistulising Crohn’s disease showed a clinical response to its StemSmart mesenchymal stem cell therapy, an 80% response rate. All participants experienced symptom improvement and no serious adverse events were recorded. The...
Man's Death Confirmed as Diphtheria-Related After Overseas Toxicology Test
The Northern Territory has reported a decline in diphtheria cases after a rapid vaccination campaign that immunised over 10,000 residents. Health officials confirmed one death in Darwin was diphtheria‑related, while another suspected fatality tested negative. Cases fell from a peak...
One Hope, One Team: We Hope Medical Group Unites for Compassionate Care
We Hope Medical Group convened its nationwide network of physicians, specialists, and health leaders for the "One Hope, One Team" assembly in Manila, reinforcing its mission to deliver dignified, patient‑centered care across the Philippines. Chairman and CEO Dr. John Paul...
The Next Frontier For GLP-1 Medications: Potential Therapy For Inflammation
A recent Cell Metabolism study found that semaglutide, a GLP‑1 medication, can alleviate osteoarthritis‑related inflammation and tissue damage independent of its weight‑loss effects. The research showed reduced cartilage degradation, fewer osteophytes, and lower pain sensitivity in pre‑clinical models. With roughly...
Asan Medical Center Unveils AI-Powered Private Search System
Asan Medical Center (AMC) in South Korea has launched an AI‑driven knowledge search system that operates entirely within a closed, on‑premises network. The platform combines a vector database with retrieval‑augmented generation (RAG) to deliver context‑aware answers from internal clinical guidelines...
Singapore, Bhutan Partner on Rural Chest X-Ray AI
Singapore’s public health system, SingHealth, has signed a two‑year memorandum of understanding with Bhutan’s Royal University and its Gyalpozhing College of Information Technology to create an AI‑assisted chest X‑ray model. The partnership will adapt the MerMED‑FM foundation model using Bhutanese...
Experts Call for Women's Heart Centers to Tackle Inequality in Diagnosis and Care
A new clinical consensus statement from the European Society of Cardiology calls for dedicated women’s heart centers across Europe to close the gender gap in cardiovascular diagnosis and treatment. The report, led by Dr. Julia Grapsa, highlights that heart disease kills...
![[Comment] The PHEIC for Ebola Disease Caused by Bundibugyo Virus: An Inflection Point for Solidarity and Health Equity](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/06bddbe006e15a02c1d5de0d04079bb0.webp)
[Comment] The PHEIC for Ebola Disease Caused by Bundibugyo Virus: An Inflection Point for Solidarity and Health Equity
On May 16, 2026 WHO Director‑General Tedros Adhanom Ghebreyesus declared a Public Health Emergency of International Concern for the Bundibugyo strain of Ebola without convening the usual Emergency Committee, underscoring the outbreak’s severity. The disease has spread across the Democratic...
New Maternal RSV Vaccine Lowers Infant Hospitalization Rates, but Accessibility May Be Limited, Study Finds
A new maternal RSV vaccine introduced in fall 2023 reduces infant hospitalizations, with the Dallas study showing zero hospitalizations among vaccinated infants versus 3% among unvaccinated. Vaccination rates varied sharply by insurance type and race, with private‑insured mothers at 37%...
Repetitive TMS Effective, Safe for Poststroke Neurogenic Overactive Bladder
A randomized controlled trial of 60 stroke survivors showed that low‑frequency contralesional repetitive transcranial magnetic stimulation (rTMS) significantly improves neurogenic overactive bladder symptoms, quality of life, and resilience scores compared with sham treatment. Benefits persisted through week 8, with mean OAB...
Response to Comments on "Aluminium Adjuvants in Vaccines and Potential Health Effects: Systematic Review"
The authors of a BMJ systematic review on aluminium adjuvants in vaccines rebut criticisms by highlighting methodological flaws in cited studies and reaffirming that no causal association has been identified. They note that the Joura 2015 HPV vaccine trial cannot...
Does Physician Education on New NCCN Guidelines Change Behavior? Data From Ontada Say, “Yes”
Ontada, a McKesson subsidiary, presented ISPOR 2026 data showing that EHR‑based, on‑demand education on new NCCN HER2‑low guidelines lifted guideline‑concordant therapy from 62% to 71% among participating oncologists. The initiative used peer‑consultations and podcasts embedded in the iKnowMed system of The...
Pioneering Cell Therapy Offers Hope for Advanced Liver Disease
A phase‑2 trial of autologous macrophage therapy showed a marked improvement in transplant‑free survival for patients with end‑stage cirrhosis. After four years, 70% of the 26 participants receiving the cell therapy remained alive without needing a liver transplant, versus 40%...
The Digital Clinic: How Ultra-Minimally Invasive Spine Procedures Are Redefining Outpatient Workflow Efficiency
Ultra‑minimally invasive spine (UMIS) surgery uses endoscopic visualization and micro‑working channels to treat spinal pathology through sub‑centimeter incisions, dramatically reducing tissue trauma and postoperative pain. The technique enables procedures under conscious sedation or regional blocks, cutting Phase I PACU stays from...
Prevent Denials by Catching Credentialing Issues
Billings Clinic–Logan Health avoided costly claim denials by overhauling its provider credentialing checks. Compliance partner Ximena Restrepo says manual verification of physicians against federal and state exclusion lists can prevent $100,000 per claim‑line penalties and $24,947 civil fines. The hospital...
Dual-Center Development and Validation of a LDL-C and TC Based Nomogram for Preoperative Hemorrhagic Risk in Adult Moyamoya Disease
A dual‑center retrospective study of 260 adult moyamoya disease (MMD) patients identified elevated low‑density lipoprotein cholesterol (LDL‑C) as an independent predictor of pre‑operative intracranial hemorrhage. Using LASSO and multivariate logistic regression, the authors built a nomogram incorporating LDL‑C and total...
Prior Authorization Is Draining Revenue, Which Is Why Automation Has Become a Strategic Imperative
Prior authorizations have become a costly bottleneck for hospitals and health systems, with physicians averaging 39 requests per week and staff spending at least 13 hours on them. The delays trigger care postponements, patient abandonment, and a cascade of preventable...
Clinical Operations Burnout Is Undermining Patient Enrollment
Clinical operations burnout is eroding patient enrollment and retention in trials, with nearly half of healthcare workers reporting burnout symptoms in 2022. Around 80% of studies miss their recruitment timelines, a problem tied to overburdened site teams handling growing protocol...
Blockbuster Sales, Lawsuits, and Approvals: Is There a Recovery in Sight for Bayer in 2026?
Bayer’s 2026 outlook mixes strong Crop Science sales with a mixed pharma portfolio. Crop Science generated $15.6 billion in Q1, while blockbuster drugs Nubeqa and Kerendia posted double‑digit growth, but Xarelto and Eylea revenues fell sharply after patent expirations. The company...
:max_bytes(150000):strip_icc():format(jpeg)/outofpocket.asp-final-8fdb440da19e4e2b939a9f85d370afb9.png)
Understanding Out-of-Pocket Expenses: Definition, Types, and Examples
Out-of-pocket expenses are the cash amounts individuals pay before insurance or employer reimbursement, covering both everyday business costs and health‑care charges such as deductibles, copays and coinsurance. The Affordable Care Act caps annual out-of-pocket limits—$9,200 for individuals in 2025, rising...
Agios Reports the EC Approval of Pyrukynd for Anemia in Alpha or Beta Thalassemia
The European Commission has granted approval for Agios' oral pyruvate kinase activator Pyrukynd (mitapivat) to treat anemia in adults with both non‑transfusion‑dependent and transfusion‑dependent alpha‑ or beta‑thalassemia. The decision follows positive results from the global Phase III ENERGIZE and ENERGIZE‑T trials,...
Do Wall Street Analysts Like ResMed Stock?
ResMed Inc., a $30.3 billion market‑cap leader in sleep‑apnea and respiratory devices, has seen its stock tumble 15.3% over the past year, underperforming the S&P 500’s 27.9% gain. Year‑to‑date, the shares are down 13.6% while the broader market rose 9.2%. The company...
Pharming Reports the EC Approval of Joenja (Leniolisib) for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
The European Commission has granted marketing authorization for Pharming’s oral PI3Kδ inhibitor Joenja (leniolisib) to treat patients aged 12 and older with activated phosphoinositide 3‑kinase delta syndrome (APDS) across all 30 EEA states. Approval is based on a Phase II/III...
We Are the Largest Oncology Player in India, Says Zydus MD; Eyes US Speciality Push
Zydus Lifesciences says it has become India’s largest oncology player, leveraging early entry into biologics like Pertuzumab and Nivolumab and a broad oral cancer portfolio. The company attributes rapid growth to government cancer schemes and robust patient‑support programs that have...
Caliway Secures FDA Clearance for CBL-514 Clinical Trial
Caliway Biopharmaceuticals received FDA clearance for its CBL‑0302 IND application, clearing the path for a pivotal global Phase III trial of CBL‑514 aimed at reducing abdominal subcutaneous fat. The double‑blind, placebo‑controlled study will enroll roughly 320 participants in the United States, Canada...
Late-Breakers to Look Out for at ASCO 2026
ASCO 2026’s late‑breaker session will unveil a slate of pivotal trials that could reshape treatment algorithms across liver, bladder, pancreatic, prostate, multiple myeloma and several rare cancers. AstraZeneca will present EMERALD‑3 and POTOMAC data, pushing its Imfinzi‑based combos into first‑line...
Newel Health and Gerresheimer Launch Strategic Collaboration
Newel Health, a developer of regulated digital medical devices, and Gerresheimer, a global drug‑delivery and packaging specialist, announced a strategic collaboration to help pharmaceutical and biotech firms embed digital endpoints, real‑world data and AI into therapies. The partnership pairs Newel’s...
Gilead Reports the US FDA Accelerated Approval of Hepcludex to Treat Chronic Hepatitis Delta Virus (HDV) Infection
Gilead Sciences received accelerated approval from the U.S. Food and Drug Administration for Hepcludex (bulevirtide‑gmod), an 8.5 mg subcutaneous injection for adults with chronic hepatitis delta virus (HDV) infection. The decision is based on data from the Phase III MYR301 trial, which...
Jardines Signals Pivot with $2.4bn Australian Radiology Deal
Jardine Matheson announced a $2.4 billion acquisition of an Australian radiology network, adding roughly 100 imaging centres to its portfolio. The deal is financed with $1 billion of cash and $1.4 billion of debt, reflecting the conglomerate’s push into health services. The move...
Healthcare Outsourcing Philippines: How AI Is Redefining Patient Care Delivery
In 2026 the Philippines has evolved from a low‑cost health‑BPO destination to a hub for AI‑augmented clinical operations, a shift dubbed “Intelligence‑Augmented Care.” Vendors are moving from headcount‑based pricing to outcome‑aligned models, delivering up to 45 % lower claim denial rates...
New Advances Improve Prevention and Treatment of HPV-Related Cancers
Human papillomavirus remains a leading cause of cervical, anal, oropharyngeal and other cancers. New prophylactic vaccines now protect against a broader set of high‑risk strains, while next‑generation candidates aim for even wider coverage. Therapeutic vaccines that target the viral E6...